Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19584438 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL16338157 | 1.00 | — | — | |
| SCHEMBL15038049 | 0.97 | — | — | |
| SCHEMBL20898998 | 0.97 | — | — | |
| SCHEMBL20898999 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL25311551 | 0.85 | CPN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL31262544 | 0.85 | CPN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL25311561 | 0.85 | CPN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL14917263 | 0.83 | CPN1 (0.35) | — | |
| SCHEMBL24100626 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| US-20250195488-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | TEIJIN PHARMA LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4491185-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | Teijin Pharma Limited (JP) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015187905-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| US-9193714-B2 | Fluorinated estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2855455-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| CN-104364249-A | Triazolo compounds as pde10 inhibitors | BOSCH GMBH ROBERT | 2015-02-18 | — | — | CN | disclosed |
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| CN-104114551-A | Fluorinated estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC | 2014-10-22 | — | — | CN | disclosed |
| WO-2013178572-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |